ANI Pharmaceuticals secures Egetis board support for SEK 5.3bn takeover of EMCITATE developer

The board of Sweden's Egetis Therapeutics has thrown its weight behind a takeover approach from US drugmaker ANI Pharmaceuticals, endorsing a cash bid worth around SEK 5.3 billion. The directors' backing, announced on 5 November 2026, was without dissent and covers holders of the company's convertibles and warrants as well as ordinary shareholders.

ANI is offering SEK 11.25 for each share. The bid only succeeds if more than 90 percent of holders tender, and it also depends on official approvals, including competition review. Investors representing about 42.2 percent of the company have already pledged to accept, according to the information available, which leaves the offer well short of the threshold but with a substantial head start.

The timing is closely tied to the product. On 28 September 2026 the US Food and Drug Administration approved EMCITATE for MCT8 deficiency, also known as Allan–Herndon–Dudley syndrome. The Egetis board said it expects ANI to speed up the medicine's American launch, though the information available gives no detail on how or on what timetable.

The material provided does not set out financing arrangements, a bid premium, an expected closing date or ANI's commercial plans for the drug, so the deal's wider financial impact remains to be seen.